| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Protein tyrosine phosphatase sigma (PTPsigma) and phosphatase of regenerating liver-3 (PRL-3/PTP4A3).
|
|---|---|
| ln Vitro |
INVIVO-2959 inhibits PRL-3 with an IC50 of 28.1 μM. By inhibiting PRL-3, it may affect cell migration, invasion, and metastasis. Detailed enzymatic and cellular activity data are available in primary research publications.
|
| ln Vivo |
PRL-3 is an oncogenic phosphatase that promotes cancer cell migration, invasion, and metastasis. INVIVO-2959, by inhibiting PRL-3 activity, may reduce these malignant properties in cancer cells. The compound is used to study the role of PRL-3 in cancer progression and metastasis.
|
| Enzyme Assay |
PRL-3 phosphatase activity is measured using phosphatase assay kits with synthetic phosphopeptide substrates (e.g., p-nitrophenyl phosphate or DiFMUP). Recombinant PRL-3 is incubated with substrate and varying concentrations of INVIVO-2959. The release of phosphate or fluorescent product is monitored to determine IC50 values.
|
| Cell Assay |
Cancer cell lines expressing high levels of PRL-3 are treated with INVIVO-2959 at various concentrations. Cell viability, migration (wound healing or transwell assays), and invasion (Matrigel assays) are assessed. PRL-3 activity and downstream signaling pathways are evaluated by Western blot.
|
| Animal Protocol |
INVIVO-2959 is typically evaluated in mouse models of cancer metastasis. Tumor-bearing or metastasis model mice are treated with INVIVO-2959 via intraperitoneal or oral administration. Metastasis formation, tumor growth, and survival are monitored.
|
| ADME/Pharmacokinetics |
INVIVO-2959 has molecular weight 297.27 and formula C15H11N3O4. It is a small-molecule phosphatase inhibitor suitable for both in vitro enzyme assays and cell-based studies. Detailed PK parameters are available in primary research publications.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity data for INVIVO-2959 are limited. As a phosphatase inhibitor, potential off-target effects on other phosphatases should be considered.
|
| References | |
| Additional Infomation |
INVIVO-2959 is a research tool for studying PRL-3 and PTPsigma biology in cancer. Its mechanism involves inhibition of PRL-3 phosphatase activity, potentially reducing cancer cell migration and invasion. No clinical trials or approved indications exist.
|
| Exact Mass |
297.075
|
|---|---|
| CAS # |
577962-95-9
|
| Appearance |
Light yellow to yellow solid powder
|
| Synonyms |
INVIVO 2959; INVIVO2959; INVIVO-2959
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
